13 Jul Maxx Orthopedics, in Partnership with Invibio Biomaterial Solutions, Announces First Primary Total Knee Arthroplasty with the PEEK-OPTIMA™ Femoral Component

Maxx Orthopedics, Inc., and Invibio Biomaterial Solutions together announced the successful study initiation and first patients to be implanted with the new, all polymer, PEEK-OPTIMA™ femoral knee component for primary total knee arthroplasty (TKA).

Maxx Orthopedics, Inc., and Invibio Biomaterial Solutions together announced the successful study initiation and first patients to be implanted with the new, all polymer, PEEK-OPTIMA™ femoral knee component for primary total knee arthroplasty (TKA). This pre-market, global feasibility study is designed to assess the safety and efficacy of the PEEK-OPTIMA™ femoral knee component in patient candidates receiving primary TKA.

The PEEK-OPTIMA™ femoral knee component combined with the Freedom® high-flex all-polyethylene tibial component provides a modern, metal-free alternative to the standard TKA. It offers surgeons and patients a femoral component that has the potential to correct component to bone material mismatch for preservation of femoral bone density, while avoiding patient complaints of metal sensitivity and achieving increased post-operative patient outcomes. Dr. John Devine, Medical Business Director of Invibio, stated “This is an exciting landmark moment, and we will now adopt a cautiously optimistic approach and await the full results of the clinical study. The potential for superior clinical outcomes and improved patient satisfaction from a metal-free implant, together with improved health economic outcomes makes this a significant advancement in orthopedic technology.”

PEEK-OPTIMA™ polymers deliver performance characteristics such as modulus and flexural strength close to that of cortical bone, contributing to bone density preservation, and radiolucent material properties that allows artifact-free imaging both during and after implantation. The polymer has proven biocompatibility and biomechanical benefits in implantable spine, trauma and other devices that provides safety, longevity and reassurance to patients and surgeons.

The PEEK-OPTIMA™ femoral component is based on Maxx Orthopedics’ Freedom® Total Knee System high-flexion, bone-conserving design. “We are and have always been focused on delivering high value. We asked how we could significantly improve patient satisfaction and PEEK is potentially that solution. We are using a time-tested material in a new way to hopefully improve bone quality and overall longevity”, said Ashesh Shah, CEO of Maxx Orthopedics.

Maxx Orthopedics and Invibio™ Biomaterial Solutions will be displaying PEEK-OPTIMA™ femoral component at the AAOS Annual Meeting, September 1-3, in San Diego, CA (Booth #3117).

For additional information, please visit http://www.maxxortho.com and http://www.invibio.com.

The PEEK-OPTIMA™ femoral component for primary TKA is not approved for sale in the United States or internationally.

About Maxx Orthopedics
Maxx Orthopedics is the manufacturer of the Freedom Knee® System, Libertas® Total Hip System and Quick Recovery Solutions (QRS®). The company develops and markets innovative orthopedic medical devices worldwide with a focus on providing state-of-the-art implants and related solutions that best restore patient mobility while accommodating lifestyle, anatomical and economic needs. Maxx Medical, Pvt. Ltd., is the parent company of Maxx Orthopedics, Inc. Find out more at http://www.maxxortho.com

About Invibio™ Biomaterial Solutions
Invibio™ Biomaterial Solutions, part of the Victrex plc group of companies, is a global leader in providing high-performance biomaterial solutions to medical device manufacturers. The company provides PEEK-OPTIMA™ polymers, advanced technical research and support and manufacturing of components for spine, trauma, and orthopedic and dental medical segments for the development of long-term implantable medical devices. Invibio’s PEEK-OPTIMA™ polymers are used in approximately 13 million implanted devices worldwide. Find out more at http://www.invibio.com.

SOURCE: PR Web, 12th July 2021